Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly PLD in Recurrent Ovarian Cancer
NCT00170573Phase 2Completed
- Sponsor
- NOGGO
- Start
- Sep 2001
- Primary completion
- Apr 2009
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by NOGGO. Primary endpoints: Occurrence of Palmar-plantar Erythrodysesthesia at 18 months and Quality of Life. Started Sep 2001; status: completed.
02
Drugs
doxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00170573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170573.